Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Clinical Characteristics and Macrolide Resistance of Mycoplasma pneumoniae in Taiwanese Children:A Post-Pandemic Analysis (2024-2025).

Created on 12 Nov 2026

Authors

Chun Liu, Shun-Cheng Yang, Chao-Jen Lin, Kan-Hsuan Lin, Cheng-Han Lee, Chih-Chi Huang, Jun-Kai Kao

Published in

The journal of medical investigation : JMI. Volume 73. Issue 3.4. Pages 344-350.

Abstract

The resurgence of Mycoplasma pneumoniae infections following the coronavirus disease 2019 pandemic has elicited significant concerns regarding alterations in epidemiology, clinical presentation, and antimicrobial resistance patterns. This study examined the clinical characteristics, co-infection profiles, and antimicrobial resistance patterns of M. pneumoniae in hospitalized Taiwanese children during the 2024-2025 surge period. This retrospective cohort study included 93 pediatric inpatients. Diagnosis was established through an integrated assessment of serum immunoglobulin M, polymerase chain reaction, and chest radiography findings, verified by two pediatric infectious disease specialists. Resistance was categorized based on clinical treatment failure (Macrolide and Clinical-resistance) or proactive use of second-line agents (Probable-resistance). Among the 79 confirmed M. pneumoniae cases, 55.7% were mono-infections, with Haemophilus influenzae identified as the most frequent bacterial co-pathogen. Macrolide, Clinical, and Probable-resistance rates were 19.0%, 31.6%, and 87.3%, respectively. A notable shift in empirical prescriptions was observed, with macrolide use declining from 38.24% to 13.73% during the study period. Radiographic severity was significantly associated with fever duration. Receiver operating characteristic analysis indicated that conventional biomarkers exhibited poor predictive power for resistance. In conclusion, clinical management should prioritize early assessment of treatment responses and clinical progress over specific biomarker thresholds in this complex post-pandemic immunological landscape. J. Med. Invest. 73 : 344-350, August, 2026.

PMID:
43014763
Bibliographic data and abstract were imported from PubMed on 12 Nov 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 3
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement